Background: Chronic liver disease (CLD) is an important cause of morbidity and mortality and can lead to hepatic fibrosis. This study was conducted to evaluate the diagnostic value of real-time shear wave elastography (SWE) in the assessment of hepatic fibrosis.Methods: A systematic search of databases was performed for publications on SWE during the period between 2010 and 2017. The identified studies were analyzed using Meta-disc 1.4 software to integrate and analyze the data.Results: Eleven studies comprising 1560 patients were included for analysis. The pooled sensitivity, specificity and diagnostic odds ratio were 0.85 (95% CI: 0.82–0.87), 0.79 (95% CI: 0.76–0.82) and 30.81 (95% CI: 16.55–57.34), respectively for patients with a Metavir-score of ≥ F2; 0.87 (95% CI: 0.84–0.91), 0.84 (95% CI: 0.82–0.87), 41.45 (95% CI:18.25–94.45), respectively for patients with ≥ F3; 0.88(95% CI: 0.83–0.91), 0.91 (95% CI: 0.89–0.92), 67.18 (95% CI:30.02–150.31), respectively for patients with ≥ F4. The areas under the receiver operating characteristic curve of the three groups were 0.9147, 0.9223 and 0.9520, respectively.Conclusions: Our work demonstrates that SWE is highly accurate for detecting and staging hepatic fibrosis.

Background: Circular RNA (circRNA) are a new class of non-coding RNAs that are involved in the molecular pathology of cancer. This study aims to screen and validate key circRNAs with diagnostic potential in o ral squamous cell carcinoma (OSCC), and explore their possible molecular mechanism. Methods: This study first integrated the GSE131182 dataset with clinically obtained OSCC sample data and used the limma package to identify differentially expressed circular RNAs (DEcircRNAs). Subsequently, circRNAs associated with head and neck squamous cell carcinoma were identified using CircNet2.0 and intersected with the differentially expressed circRNAs to determine the key circRNA. The diagnostic value of the key circRNA was evaluated using receiver operating characteristic (ROC) curves, followed by functional validation through in vitro assays including cell counting kit-8 (CCK-8), wound healing, transwell assay, and flow cytometry. Finally, target microRNAs (miRNAs) were predicted using CircNet2.0 and miRDB, a ceRNA network was constructed, and functional enrichment analysis of target genes was performed using Metascape tool. Results: A total of 318 and 46 differentially expressed circRNAs (DEcircRNAs) were identified from the GSE131182 dataset and clinical samples, respectively. Through intersection analysis, the key circRNA hsa_circ_0000831 was identified. hsa_circ_0000831 was upregulated in OSCC samples, and ROC curve analysis indicated its high diagnostic performance. In vitro experiments showed that inhibition of hsa_circ_0000831 significantly reduced OSCC cell viability, migration, and invasion, while markedly enhancing apoptosis. ceRNA network analysis predicted that hsa_circ_0000831 targets five miRNAs (including hsa-miR-136-5p, hsa-miR-100-3p, hsa-miR-144-5p, hsa-miR-149-5p and hsa-miR-214-5p), with the associated target genes mainly enriched in cancer-related pathways. Conclusion: This work offer s a novel foundation for the early identification of OSCC and provides potential clues for finding new therapeutic targets.

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, resulting in hypophosphatemia and altered bone turnover. It is most frequently caused by phosphaturic mesenchymal tumors (PMTs), a rare and distinct group of neoplasms. Patients with TIO exhibit clinical features of osteomalacia, including bone and muscle pain, severe muscle weakness, gait disturbance, and increased susceptibility to fracture. PMTs exhibit pananatomic distribution, in soft tissue or bones, but are most commonly found in the lower extremities, followed by the head and neck. Most head and neck tumors are located in the sinus area, while jaw involvement is exceptionally rare. Diagnosis is difficult and the misdiagnosis rate is high. A case PMT occurring in the jaws are presented to highlight diagnostic features and challenges. Notably, PMTs are benign tumors and their removal results in correction of the biochemical aberrations that underly the TIO.